Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration

被引：0
|
作者：
Mirataollah Salabati
Anthony Obeid
Raziyeh Mahmoudzadeh
Omesh Gupta
Allen Chiang
Marc Spirn
Michael A. Klufas
Jason Hsu
机构：
[1] Mid Atlantic Retina,
[2] The Retina Service of Wills Eye Hospital,undefined
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2022年 / 260卷
关键词：
Age-related macular degeneration; Switch; Aflibercept; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2509 / 2516
页数：7
相关论文
共 50 条
  • [1] Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration
    Salabati, Mirataollah
    Obeid, Anthony
    Mahmoudzadeh, Raziyeh
    Gupta, Omesh
    Chiang, Allen
    Spirn, Marc
    Klufas, Michael A.
    Hsu, Jason
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2509 - 2516
  • [2] Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
    Mantel, Irmela
    Gillies, Mark C.
    Souied, Eric H.
    SURVEY OF OPHTHALMOLOGY, 2018, 63 (05) : 638 - 645
  • [3] UK outcomes of switching patients with neovascular age-related macular degeneration from ranibizumab to aflibercept
    Manjunath, Vina
    Talks, James S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [4] Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration
    Florian M. Heussen
    Qing Shao
    Yanling Ouyang
    Antonia M. Joussen
    Bert Müller
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252 : 909 - 915
  • [5] Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration
    Heussen, Florian M.
    Shao, Qing
    Ouyang, Yanling
    Joussen, Antonia M.
    Mueller, Bert
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 252 (06) : 909 - 915
  • [6] Comparison of outcomes after switching treatment from intravitreal bevacizumab or ranibizumab to aflibercept in neovascular age-related macular degeneration
    Venzara, Frank
    Mason, John
    Glover, Jay
    McGwin, Gerald
    Huisingh, Carrie
    Friedman, Duncan
    Feist, Richard
    Thomley, Martin
    Albert, Michael
    Price, Natalie
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [7] Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
    Barthelmes, Daniel
    Campain, Anna
    Phuc Nguyen
    Arnold, Jennifer J.
    McAllister, Ian L.
    Simpson, Judy M.
    Hunyor, Alex P.
    Guymer, Robyn
    Essex, Rohan W.
    Morlet, Nigel
    Gillies, Mark C.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2016, 100 (12) : 1640 - 1645
  • [8] Twelve-month outcomes of aflibercept versus ranibizumab for neovascular age-related macular degeneration (AMD)
    Almuhtaseb, Hussein
    Michaels, Luke
    Vardarinos, Thanos
    Lotery, Andrew J.
    EYE, 2018, 32 (11) : 8 - 10
  • [9] Visual outcomes of eyes with neovascular age-related macular degeneration requiring frequent ranibizumab when switched to aflibercept
    Ellabban, Abdallah
    Sallam, Ahmed
    Petousis, Vasileios
    Fletcher, Emily
    Mohamed, Quresh
    Johnston, Robert
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [10] CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT
    Mantel, Irmela
    Gianniou, Christina
    Dirani, Ali
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (01): : 53 - 58
12345